Cannabis Abstinence and Neurocognitive Assessment in Adolescence (NCT07160153) | Clinical Trial Compass
RecruitingNot Applicable
Cannabis Abstinence and Neurocognitive Assessment in Adolescence
Czechia29 participantsStarted 2024-12-03
Plain-language summary
Cannabis Abstinence and Neurocognitive Assessment in Adolescence
Who can participate
Age range15 Years – 18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.
Exclusion Criteria:
* psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
* somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
* Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.